This page shows the latest ALK inhibitor news and features for those working in and with pharma, biotech and healthcare.
Fourth to market aims to carve out niche. EU regulators have approved Pfizer’s PARP inhibitor Talzenna to treat patients with BRCA-mutated breast cancer, opening up another front in a ... Talzenna is one of four new targeted therapies it is hoping will
Last November, the drugmaker claimed FDA approval for Xalkori follow-up Lorbrena (lorlatinib) in second-line ALK-positive NSCLC and SMO inhibitor Daurismo (glasdegib) for acute myeloid leukaemia, while in October ... it got a green light for PARP
The FDA has granted approval to Pfizer's next generation ALK inhibitor lung cancer treatment Lorbrena, which will help it defend its presence in the market. ... Follow-up ALK inhibitors are important in this treatment pathway, as many experience tumour
Among the highlights cited by Read on the call were oncology drugs talazoparib - a PARP inhibitor due for filing shortly for breast cancer - along with ALK/ROS1 inhibitor lorlatinib and EGFR ... inhibitor dacomitinib for lung cancer, which are due for
Pfizer has filed for approval of its third-generation ALK inhibitor lorlatinib, a follow-up to its first-generation Xalkori product which is facing increasing competition. ... Lorlatinib was developed by Pfizer scientists with the specific goal of
Roche’s oncology business unit chalked up two FDA approvals this week for its new ALK inhibitor Alecensa in first-line lung cancer and BRAF inhibitor Zelboraf in a rare blood ... That allows Roche’s drug to take on Pfizer’s drug - as well as
More from news
Approximately 1 fully matching, plus 31 partially matching documents found.
CMC is a leading global agency dedicated to healthcare communications across the lifecycle. We combine scientific acumen, excellence in delivery...